Cypress Wealth Services LLC Has $1.83 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Cypress Wealth Services LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 3.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,065 shares of the company’s stock after selling 71 shares during the quarter. Cypress Wealth Services LLC’s holdings in Eli Lilly and Company were worth $1,829,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swedbank AB bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $932,797,000. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 1.6% in the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock valued at $56,592,709,000 after buying an additional 1,133,810 shares in the last quarter. Wulff Hansen & CO. increased its holdings in shares of Eli Lilly and Company by 90,438.0% during the second quarter. Wulff Hansen & CO. now owns 937,068 shares of the company’s stock worth $848,403,000 after buying an additional 936,033 shares in the last quarter. GQG Partners LLC raised its stake in shares of Eli Lilly and Company by 20.2% in the first quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock valued at $2,994,280,000 after acquiring an additional 648,094 shares during the last quarter. Finally, Comerica Bank boosted its holdings in shares of Eli Lilly and Company by 71.6% in the 2nd quarter. Comerica Bank now owns 1,512,983 shares of the company’s stock worth $1,369,825,000 after acquiring an additional 631,312 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on LLY shares. BMO Capital Markets boosted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Bank of America boosted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Wells Fargo & Company raised their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $979.29.

Eli Lilly and Company Stock Down 0.7 %

Shares of NYSE:LLY traded down $6.69 during midday trading on Thursday, hitting $913.05. The stock had a trading volume of 66,409 shares, compared to its average volume of 3,004,967. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The business’s 50-day simple moving average is $906.72 and its 200-day simple moving average is $850.80. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company has a market cap of $867.77 billion, a P/E ratio of 136.08, a PEG ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, sell-side analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.